menu
    • menu

    Company profile for Meissa Vaccines

    NEW Drugs in Dev: 5
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Meissa Vaccines is a pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial virus (RSV). Our innovative platform technology for viral genetic engineering can be applied to multiple pathogens. Our passion is child health, but our vaccine programs have the potential to benefit multiple age and population groups. Successful vaccine...
    Meissa Vaccines is a pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial virus (RSV). Our innovative platform technology for viral genetic engineering can be applied to multiple pathogens. Our passion is child health, but our vaccine programs have the potential to benefit multiple age and population groups. Successful vaccines for RSV and related viruses will have widespread benefits for society and families.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Meissa VaccinesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    JLABS, 329 Oyster Point Boulevard, 3rd Floor South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.meissavaccines.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/meissa-vaccines/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/meissavaccines

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Layoffs at Meissa Vaccines as biotech's future lies in limbo
    Layoffs at Meissa Vaccines as biotech's future lies in limbo

    05 Mar 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/meissa-vaccines-future-limbo-due-current-fundraising-climate-ceo

    FIERCE BIOTECH
    05 Mar 2024
    Share Share
    Meissa Vaccines Announces Positive Clinical Data for the First RSV Vaccine
    Meissa Vaccines Announces Positive Clinical Data for the First RSV Vaccine

    08 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230808124808/en

    BUSINESSWIRE
    08 Aug 2023
    Share Share
    Meissa Vaccines Enters into cGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate for Phase 2 Clinical Trials
    Meissa Vaccines Enters into cGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate for Phase 2 Clinical Trials

    28 Jun 2023

    // PRESS RELEASE

    https://exothera.world/meissa-vaccines-enters-into-cgmp-manufacturing-agreement-for-pediatric-rsv-vaccine-candidate-for-phase-2-clinical-trials/

    PRESS RELEASE
    28 Jun 2023
    Share Share
    Meissa Vaccines Announces Positive Data for Intranasal Live Attenuated RSV
    Meissa Vaccines Announces Positive Data for Intranasal Live Attenuated RSV

    07 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221107005432/en

    BUSINESSWIRE
    07 Nov 2022
    Share Share
    Meissa Presented at The White House Summit on Future of COVID-19 Vaccines
    Meissa Presented at The White House Summit on Future of COVID-19 Vaccines

    27 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220726006074/en

    BUSINESSWIRE
    27 Jul 2022
    Share Share
    Meissa Vaccines Appoints Frank Glavin Chief Executive Officer
    Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

    11 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220711005060/en

    BUSINESSWIRE
    11 Jul 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search